Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458159 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00458159 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 34 participants.
The verdict
NCT00458159, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.
Interventions
- DRUG CC-11006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-05-01 |
| Est. Completion | 2008-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458159
The ClinicalTrials.gov registry entry for NCT00458159 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-11006 is the first listed.
NCT00458159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458159 about?
NCT00458159 is a clinical study titled "A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes". A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes.
What is the current status of trial NCT00458159?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2007-05-01. Estimated completion is 2008-12-01.
What interventions are being tested in trial NCT00458159?
The interventions under investigation include: CC-11006 (DRUG).
Who is sponsoring clinical trial NCT00458159?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.